InnoCare Pharma Limited

SEHK:9969 Stock Report

Market Cap: HK$12.9b

InnoCare Pharma Management

Management criteria checks 3/4

InnoCare Pharma's CEO is Jasmine Cui, appointed in Aug 2016, has a tenure of 8.25 years. total yearly compensation is CN¥22.63M, comprised of 20.8% salary and 79.2% bonuses, including company stock and options. directly owns 5.73% of the company’s shares, worth HK$739.46M. The average tenure of the management team and the board of directors is 3.2 years and 9 years respectively.

Key information

Jasmine Cui

Chief executive officer

CN¥22.6m

Total compensation

CEO salary percentage20.8%
CEO tenure8.3yrs
CEO ownership5.7%
Management average tenure3.2yrs
Board average tenure9yrs

Recent management updates

Recent updates

Is InnoCare Pharma (HKG:9969) A Risky Investment?

Oct 21
Is InnoCare Pharma (HKG:9969) A Risky Investment?

Subdued Growth No Barrier To InnoCare Pharma Limited (HKG:9969) With Shares Advancing 29%

Sep 13
Subdued Growth No Barrier To InnoCare Pharma Limited (HKG:9969) With Shares Advancing 29%

Analyst Estimates: Here's What Brokers Think Of InnoCare Pharma Limited (HKG:9969) After Its Half-Yearly Report

Aug 22
Analyst Estimates: Here's What Brokers Think Of InnoCare Pharma Limited (HKG:9969) After Its Half-Yearly Report

Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?

Jun 21
Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?

Some Analysts Just Cut Their InnoCare Pharma Limited (HKG:9969) Estimates

Apr 02
Some Analysts Just Cut Their InnoCare Pharma Limited (HKG:9969) Estimates

Is InnoCare Pharma (HKG:9969) Weighed On By Its Debt Load?

Feb 14
Is InnoCare Pharma (HKG:9969) Weighed On By Its Debt Load?

Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?

Oct 06
Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?

Is InnoCare Pharma (HKG:9969) Using Too Much Debt?

May 11
Is InnoCare Pharma (HKG:9969) Using Too Much Debt?

Is There An Opportunity With InnoCare Pharma Limited's (HKG:9969) 36% Undervaluation?

Apr 11
Is There An Opportunity With InnoCare Pharma Limited's (HKG:9969) 36% Undervaluation?

Is InnoCare Pharma (HKG:9969) A Risky Investment?

Jan 25
Is InnoCare Pharma (HKG:9969) A Risky Investment?

Despite Lacking Profits InnoCare Pharma (HKG:9969) Seems To Be On Top Of Its Debt

Sep 05
Despite Lacking Profits InnoCare Pharma (HKG:9969) Seems To Be On Top Of Its Debt

InnoCare Pharma (HKG:9969) Is Using Debt Safely

Apr 30
InnoCare Pharma (HKG:9969) Is Using Debt Safely

CEO Compensation Analysis

How has Jasmine Cui's remuneration changed compared to InnoCare Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-CN¥376m

Jun 30 2024n/an/a

-CN¥471m

Mar 31 2024n/an/a

-CN¥761m

Dec 31 2023CN¥23mCN¥5m

-CN¥631m

Sep 30 2023n/an/a

-CN¥584m

Jun 30 2023n/an/a

-CN¥867m

Mar 31 2023n/an/a

-CN¥781m

Dec 31 2022CN¥24mCN¥4m

-CN¥887m

Sep 30 2022n/an/a

-CN¥987m

Jun 30 2022n/an/a

-CN¥296m

Mar 31 2022n/an/a

-CN¥78m

Dec 31 2021CN¥29mCN¥3m

-CN¥65m

Sep 30 2021n/an/a

CN¥60m

Jun 30 2021n/an/a

-CN¥266m

Mar 31 2021n/an/a

-CN¥329m

Dec 31 2020CN¥120mCN¥1m

-CN¥391m

Sep 30 2020n/an/a

-CN¥2b

Jun 30 2020n/an/a

-CN¥2b

Mar 31 2020n/an/a

-CN¥2b

Dec 31 2019CN¥17mCN¥3m

-CN¥2b

Sep 30 2019n/an/a

-CN¥742m

Jun 30 2019n/an/a

-CN¥592m

Mar 31 2019n/an/a

-CN¥571m

Dec 31 2018CN¥26mCN¥2m

-CN¥550m

Compensation vs Market: Jasmine's total compensation ($USD3.12M) is above average for companies of similar size in the Hong Kong market ($USD487.93K).

Compensation vs Earnings: Jasmine's compensation has been consistent with company performance over the past year.

CEO

Jasmine Cui (61 yo)

8.3yrs

Tenure

CN¥22,626,000

Compensation

Dr. Jisong Cui, Ph.D. also known as Jasmine, has been Co-Founder InnoCare Pharma, Ltd. and serves as Chief Executive Officer of InnoCare Pharma, Ltd. since August 18, 2016 and its Chairwoman since Septembe...

Leadership Team

NamePositionTenureCompensationOwnership
Jisong Cui
Co-Founder8.3yrsCN¥22.63m5.73%
HK$ 739.5m
Renbin Zhao
VP of Clinical Development & Medical Research and Executive Directorno dataCN¥4.06m8.21%
HK$ 1.1b
Xin Fu
Chief Financial Officerless than a yearno datano data
Nan Gao
Chief Operating Officer3.3yrsno datano data
Yue Tan
Accounting Supervisorno datano datano data
Xiangyang Chen
Chief Technology Officer5.1yrsno data0.0071%
HK$ 915.4k
Junsu Wang
General Counsel3.2yrsno datano data
Davy Ouyang
VP & Head of Biology3.2yrsno datano data
Jeff Chen
Chief Commercial Officerless than a yearno datano data
Bei Yuan
Secretary of the Boardno datano datano data

3.2yrs

Average Tenure

52.5yo

Average Age

Experienced Management: 9969's management team is considered experienced (3.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jisong Cui
Co-Founder9yrsCN¥22.63m5.73%
HK$ 739.5m
Renbin Zhao
VP of Clinical Development & Medical Research and Executive Director9yrsCN¥4.06m8.21%
HK$ 1.1b
Arnold Levine
Member of Scientific Advisory Boardno datano datano data
Yigong Shi
Non-Executive Director & President of Scientific Advisory Board9yrsno data0.18%
HK$ 22.7m
Zemin Zhang
Member of Scientific Advisory Board9yrsno datano data
Zhanguo Li
Member of Scientific Advisory Boardno datano datano data
Ronggang Xie
Non-Executive Director3.7yrsno datano data
Lan Hu
Independent Non-Executive Director4.7yrsno datano data
Dandan Dong
Independent Non-Executive Director1.1yrsno datano data

9.0yrs

Average Tenure

55.5yo

Average Age

Experienced Board: 9969's board of directors are considered experienced (9 years average tenure).